(Reuters) - The U.S. Patent and Trademark Office ruled in favor of Eli Lilly and Co in a patent dispute over its cancer drug Alimta with Neptune Generics LLC and Sandoz Inc.


Alimta, Lilly's top-selling oncology treatment, generated sales of $2.3 billion last year.

(Reporting by Tamara Mathias in Bengaluru; Editing by Anil D'Silva)